Xanomeline

Xanomeline is a muscarinic acetylcholine receptor agonist that has been studied for its potential therapeutic uses, particularly in the treatment of Alzheimer's disease and schizophrenia. It was first synthesized in the late 20th century and has been the subject of numerous clinical trials.

History[edit | edit source]

Xanomeline was first synthesized in the 1990s by scientists at Lilly Research Laboratories. The compound was developed as a potential treatment for Alzheimer's disease and schizophrenia, due to its ability to stimulate muscarinic acetylcholine receptors in the brain.

Pharmacology[edit | edit source]

Xanomeline is a muscarinic acetylcholine receptor agonist. It has a high affinity for the M1 and M4 subtypes of this receptor, which are primarily found in the brain. By stimulating these receptors, xanomeline can increase the activity of the cholinergic system, which is often impaired in individuals with Alzheimer's disease and schizophrenia.

Clinical Trials[edit | edit source]

Several clinical trials have been conducted to evaluate the efficacy of xanomeline in treating Alzheimer's disease and schizophrenia. In a phase II trial conducted by Lilly Research Laboratories, xanomeline was found to improve cognitive function and reduce psychotic symptoms in patients with Alzheimer's disease. However, the drug also caused significant side effects, including nausea and increased salivation, which led to the discontinuation of the trial.

Current Status[edit | edit source]

As of 2021, xanomeline is not approved for use in any country. However, research into its potential therapeutic uses continues. A prodrug of xanomeline, known as KarXT, is currently being developed by Karuna Therapeutics for the treatment of schizophrenia and other psychiatric disorders.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

v t e Schizophrenia
Causes and risk factors	Risk factors of schizophrenia 17q12 microdeletion syndrome Animal model of schizophrenia Dopamine hypothesis of schizophrenia Estrogen Epigenetics of schizophrenia Evolution of schizophrenia Evolutionary approaches to schizophrenia Glutamate hypothesis of schizophrenia Imprinted brain hypothesis Mechanisms of schizophrenia Sex differences in schizophrenia
Diagnosis and management	Kiddie Schedule for Affective Disorders and Schizophrenia LY-404,039 Metacognitive training Positive and Negative Syndrome Scale Schizophrenia Research Foundation
Symptoms and prognosis	Oneiroid syndrome Physical health in schizophrenia Post-schizophrenic depression Primary polydipsia Visual processing abnormalities in schizophrenia
Types	Childhood schizophrenia Disorganized schizophrenia Kandinsky–Clérambault syndrome Pseudoneurotic schizophrenia Simple-type schizophrenia
History	Dementia praecox Insulin shock therapy Montreal experiments Colorado v. Connelly
Comparisons and relationships	Bipolar disorder Religion and schizophrenia Schizophrenia and tobacco smoking Social construction of schizophrenia
Category